Novavax’s closely watched COVID-19 vaccine is on track for full approval after additional discussions with the Food and Drug ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

SK bioscience won a patent case against Moderna in Korea, impacting mRNA technology development and potential vaccine exports ...

SK bioscience Co., the biopharmaceutical arm of South Korea's SK Group, said Wednesday it has achieved a "final victory" in a ...

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

US stocks skyrocketed higher after President Donald Trump announced that he authorized a 90-day pause on the “reciprocal” tariffs that had gone into effect Wednesday, with the exception of ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global ...

Moderna stock has dropped more than 70% over the past year. The company’s coronavirus vaccine no longer is driving outsized growth -- and Moderna is still in the process of ushering in newer ...

Tesla (TSLA) shares fell 1.7% on Monday but were up 3.8% in pre-market trading on Tuesday. Shares in Moderna (MRNA) sunk nearly 9% on Monday, after it was announced over the weekend that US Food and ...